We are live on ! Find out more
KALA icon

KALA BIO

61 hedge funds and large institutions have $452M invested in KALA BIO in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

51% more capital inflows, than outflows

Capital inflows: $97.7M | Capital outflows: $64.5M

40% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $2.64M

39% more funds holding

Funds holding: 44 → 61 (+17)

3.54% more ownership

Funds ownership: 73.57% → 77.11% (+3.5%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
61
Holders Change
+17
Holders Change %
+38.64%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
26
Increased
14
Reduced
9
Closed
9
Calls
$3.7M
Puts
$2.64M
Net Calls
+$1.06M
Net Calls Change
+$9.36M

KALA Hedge Fund Activity: Q2 2020 in Review

61 of the 4,891 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q2 2020, worth a combined $452M — up 28% from $353M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new KALA positions and 9 closed out — a net gain of 17 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $20.4M. The largest seller was Caxton Corporation, cutting an estimated $14.4M.

  • 61 institutional investors held KALA BIO (KALA) as of Q2 2020, up from 44 in Q1 2020.
  • Funds reported $452M of KALA BIO stock for Q2 2020, up 28% quarter-over-quarter.
  • 26 funds opened new KALA BIO positions in Q2 2020 and 9 closed out, a net change of +17 holders.
  • The largest KALA BIO buyer in Q2 2020 was Fidelity Investments, an estimated $20.4M added.
  • The largest KALA BIO seller in Q2 2020 was Caxton Corporation, an estimated $14.4M sold.

Based on aggregated 13F filings for Q2 2020.